Federated Hermes Inc. Sells 183,118 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Federated Hermes Inc. reduced its holdings in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 4.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,416,332 shares of the company’s stock after selling 183,118 shares during the period. Federated Hermes Inc. owned about 0.06% of Eyepoint Pharmaceuticals worth $62,889,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. RWC Asset Management LLP purchased a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth $231,000. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth $50,000. Nisa Investment Advisors LLC lifted its position in Eyepoint Pharmaceuticals by 1,020.7% during the third quarter. Nisa Investment Advisors LLC now owns 32,500 shares of the company’s stock valued at $463,000 after purchasing an additional 29,600 shares in the last quarter. SG Americas Securities LLC bought a new stake in Eyepoint Pharmaceuticals during the third quarter valued at about $235,000. Finally, Simplify Asset Management Inc. increased its position in Eyepoint Pharmaceuticals by 13.8% in the third quarter. Simplify Asset Management Inc. now owns 90,440 shares of the company’s stock worth $1,288,000 after buying an additional 10,968 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

EYPT stock opened at $14.75 on Friday. Eyepoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $19.11. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.93 and a beta of 1.63. The business has a 50 day simple moving average of $16.34 and a two-hundred day simple moving average of $13.51.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The company had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $3.33 million. Sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on EYPT shares. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Royal Bank Of Canada upped their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Mizuho set a $28.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $29.25.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.46% of the stock is currently owned by insiders.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.